Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Gains from Sales and Divestitures (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $333865.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 8.5% year-over-year to $333865.0, compared with a TTM value of $333865.0 through Dec 2025, down 8.5%, and an annual FY2025 reading of $333865.0, down 8.5% over the prior year.
  • Gains from Sales and Divestitures was $333865.0 for Q4 2025 at Catalyst Pharmaceuticals, down from $364861.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $364861.0 in Q4 2024 and bottomed at $333865.0 in Q4 2025.